Erythropoietin Receptor (EPOR) Gene Mutation Analysis
The EPOR gene is located on the short (p) arm of chromosome 19 at position 13.2 and encodes the erythropoietin receptor, a member of the cytokine receptor family. When erythropoietin binds to the erythropoietin receptor on red cell precursors, the receptor is activated and stimulates several signaling pathways (particularly the JAK/STAT pathway) that result in the formation and maturation of red blood cells. Mutations in EPOR gene may cause familial erythrocytosis. Dysregulation of this gene may also affect the growth of certain tumors.
Familial erythrocytosis also known as familial polycythemia is an inherited condition characterized by an increased number of red blood cells (polycythemia) which may result in signs of hyperviscosity (headache, dizziness, fatigue, lassitude, visual and auditory disturbances, paresthesias and myalgia). Patients may also have mental status changes secondary to decreased oxygen delivery and are at increased risk of arterial and venous thrombosis. To date 20 pathogenic mutations have been associated with primary polycythemia and most occur in exon 8 of the gene which codes for the C-terminal negative regulatory domain. Most mutations are small insertions or deletions that result in a truncated cytoplasmic domain and loss of the negative regulatory domain. The lack of the inhibitory domain allows for continued production of red blood cells even after erythropoietin levels have decreased. Patients have elevated RBC, hemoglobin and hematocrit levels for age, low levels of erythropoietin and demonstrate normal hemoglobin oxygen affinity. The diagnosis of familial erythrocytosis can be confirmed by detection of a heterozygous pathogenic variant in EPOR gene by molecular genetic testing.
- Diagnostic confirmation of primary familial or congenital polycythemia (PFCP)
- To aid in differentiating inherited polycythemia from acquired polycythemia
- Screening at-risk relatives for a known familial EPOR mutation
Positive
- Mutation or pathogenic variant in EPOR gene. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants. Primary familial or congenital polycythemia diagnosis is confirmed.
Negative
- No mutation or pathogenic variant in EPOR gene. Primary familial or congenital polycythemia diagnosis less likely but not excluded.
Negative for mutation or pathogenic variant in EPOR gene
Whole Blood (EDTA).
Stability
Whole Blood
- Ambient: 3-5 days
- Refrigerated: 7-14 days
- Frozen: Unacceptable
- J Investig Med. 2011;59: 1067-72. [PMID: 21307776]
- Br J Haematol. 2010;148: 844-52. [PMID: 20096014]
- Am J Hematol. 2009;84: 46-54. [PMID: 19006225]
- Haematologica. 2008;93: 1072-5. [PMID: 18492694]
- Mol Cell. 2001;7: 377-85. [PMID: 11239466]
- Trends Endocrinol Metab. 1999;10: 18-23. [PMID: 10322390]
- Blood. 1999;94: 2530-2. [PMID: 10498627]
- Genetics Home Reference. Available: https://ghr.nlm.nih.gov/gene/EPOR#